Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 06/30/25 → 07/27/25 |
Funding
- DalCor Pharmaceuticals Canada Incorporated: $18,090.00
MHI: A Phase III, Double-blind, Randomized Placebo-Controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovasclar (CV) Risk in a Genetically Defined Population with a Recent Acute Coronary Syndrome (ACS): The DAL-302 Trial
- Rahman, Tahmid (PI)
- Chen, On (CoPI)
- Farooq, Kanwal (CoPI)
- Skopicki, Hal (CoPI)
- Albertus, Patrick (CoPI)
- Ibtida, Ishmam (CoPI)
Project: Research